A carregar...
Adjusting for treatment switching in the METRIC study shows further improved overall survival with trametinib compared with chemotherapy
Trametinib, a selective inhibitor of mitogen‐activated protein kinase kinase 1 (MEK1) and MEK2, significantly improves progression‐free survival compared with chemotherapy in patients with BRAF V600E/K mutation–positive advanced or metastatic melanoma (MM). However, the pivotal clinical trial permit...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4864810/ https://ncbi.nlm.nih.gov/pubmed/27172483 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.643 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|